Sorry, yes, I do know what I own. That author largely centers thier analysis on opinion, of which I don't share. The first fault is with the subtleties with coprimary endpoints. My opinion is that they have thier assessment backward. Additionally, while ADL may not have meet significance, it is my opinion that this measure is more subjective. I'll admit, I did not read the entire document as the "tone" of the document was biased from the get go. Alot of conjecture. I'm encouraged by results thus far and am excited to see progress in this field that has been stuck in a big pharma swamp for years. In my opinion, the publicly available trial data by far exceeds the results of anything to date. The only thing that would preclude this is if there was tampering with data, which I believe there has not been. I do reserve my right as a shareholder to share my opinion on my continued disappointment in timing and sharing of information. This is easier than what they are making it, but it appears the culture of Anavex is very defensive.
Market Data 
Markets 
AI
